SCHEMBL26316616

SCHEMBL26316616

Cc1ccc(/C=C/c2nc(CNc3ccc(CCCCN=[N+]=[N-])cc3)co2)cc1

nearest known ligand 0.60

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 17/20 0.60
MINK1 Q8N4C8 1/20 0.35
ADRB2 P07550 1/20 0.32
FFAR1 O14842 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22398254 0.89 ERBB2 (0.67) ERBB2MINK1
SCHEMBL22398256 0.89 ERBB2 (0.67) ERBB2MINK1
SCHEMBL26316613 0.86 ERBB2 (0.64) ERBB2MINK1FFAR1
SCHEMBL26316567 0.83 ERBB2 (0.51) ERBB2MINK1ADRB2FFAR1
SCHEMBL22398252 0.79 ERBB2 (0.45) ERBB2
SCHEMBL30632883 0.79 ERBB2 (0.45) ERBB2
SCHEMBL26316610 0.79 ERBB2 (0.58) ERBB2MINK1
SCHEMBL29937224 0.75 ERBB2 (1.00) ERBB2
SCHEMBL24111960 0.74 ERBB2 (0.71) ERBB2MINK1
SCHEMBL22397877 0.74 ERBB2 (0.71) ERBB2MINK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF UNIV MONTREAL (CA) 2023-11-09 US disclosed
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof Université de Montréal (CA) 2023-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357221-A1 HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF IDH2, TFAM, IDH1 ERBB2 2558/4885MINK1 1781/4885ADRB2 4491/4885
US-11760754-B2 Heterocyclic mitochondrial activity inhibitors and uses thereof IDH2, TFAM, NUTF2 ERBB2 2443/4885MINK1 1986/4885ADRB2 4511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.